Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against #COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 | MMWR
Évaluation de l’efficacité des #vaccins à ARN chez les sujets de 65 ans et plus.
In a multistate network of U.S. hospitals during January–March 2021, receipt of Pfizer-BioNTech or Moderna COVID-19 vaccines was 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years.
Mais, entre autres faiblesses de l’étude énumérées par les auteurs mêmes, les intervalles de confiance sont très larges.
Matériel et Méthode :
Case-patients were those who received one or more positive test results for SARS-CoV-2. Patients meeting eligibility criteria who received negative SARS-CoV-2 RT-PCR test results served as controls.
A standard approach to postmarketing VE [vaccine effectiveness ] evaluation involves the test-negative design in which vaccine performance is assessed by comparing the odds of antecedent vaccination among case-patients with acute laboratory-confirmed COVID-19 and control-patients without acute COVID-19 (6).
[The] final analysis includ[ed] 187 case-patients and 230 controls, [...] median age was 73 years for case-patients and controls.